YourChoice Therapeutics Direct Investment Page

YourChoice Follow-on Investment Opportunity

We’re pleased to announce that YourChoice has signed a Series A term sheet with North South Ventures for a $5M round of financing. Portfolia’s FemTech III and Rising America III Fund will exercise their super pro rata rights to invest in this round. Portfolia has secured a super pro rata allocation of up to $1M exclusively for the YourChoice Direct Investors who participated in the prior special purpose vehicle. Investors were emailed on Wednesday, 7/2 with details on their pro rata allocation. For questions about your allocation please reach out to ops@portfolia.com.

YourChoice Co-Founder & CEO, Akash Bakshi, will join Portfolia investors for a live overview and Q&A session on July 8th at 10 am PST. Register below to secure your spot.

7/8 RSVP

Deal Room

YourChoice Therapeutic's most recent presentation was at the 2025 Portfolia Annual Summit - Click Below to view the latest update:

YourChoice Therapeutics develops non-hormonal contraceptives designed to eliminate the risk of negative side effects associated with traditional hormonal contraceptives. The company's contraceptives work by blocking a protein in sperm required for fertilization, enabling customers to use safe birth control options with no side effects for men and women.

SPV Legal Name: Portfolia 2022 SPV 3 LLC (YourChoice SPV) | EIN: 88-2739443

Portfolio Company | In the News

YourChoice Therapeutics Completes Phase 1a Clinical Study for First Hormone-Free Male Birth Control Pill

June 03, 2024

YourChoice Therapeutics Advances Hormone-Free Male Birth Control Pill to Second Human Study
FemTech Insider

October 1, 2024

Performance Overview

Quarterly Reports

The highlights of Q1 2025 updates as provided by the company. Please note all updates provided are confidential and not for distribution. To access the file, use password: Q125YCSPV!

access the report